Article ID Journal Published Year Pages File Type
8790887 American Journal of Ophthalmology Case Reports 2018 4 Pages PDF
Abstract
A majority of Medicare beneficiaries with BVO received bevacizumab compared to ranibizumab from 2010 to 2013, with significant geographic variation in the use of the two anti-VEGF agents. Future research into factors driving geographic variation in the use of these agents may help direct cost-effective strategies for the management of BVO.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Preview
The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
Authors
, , , , , ,